“The University of Minnesota is conducting the nation's first randomized trial of a controversial anti-parasite drug that has a fervent U.S. following and is being used on the black market against COVID-19 across the globe.”
Now, will they do a good trial or give it to the wrong patients? There are three primary outcomes. Measure blood oxygen (<93%), did you have to use the emergency room, and PASC assessment questionnaire. Secondary outcome measures seem to be measured very late and do not start until 14-days.
Also, the laboratory outcomes are only for the first 70-patients. So those statistics will be very weak and not tell you much. And further notice that these 70 patients probably have their labs complete and with Ivermectin added so late, we doubt that any ivermectin patients will have any of the labs. We think this study design is extremely poor and maybe that is the way they want it. Prove us wrong U of M.
See the first comment to find the clinical trial.Read more
Please forgive us, but we seem to have heard this before.Read more
Ah, Yes. What could possibly go wrong? “Predictive modeling that guided Minnesota’s initial response to COVID-19 is being “recalibrated” with the latest pandemic data and will offer new forecasts about the spread of the infectious disease.”Read more